Read by QxMD icon Read

primary progressive multiple sclerosis

Luis Ruano, Emilio Portaccio, Benedetta Goretti, Claudia Niccolai, Milton Severo, Francesco Patti, Sabina Cilia, Paolo Gallo, Paola Grossi, Angelo Ghezzi, Marco Roscio, Flavia Mattioli, Chiara Stampatori, Maria Trojano, Rosa Gemma Viterbo, Maria Pia Amato
BACKGROUND: There is limited and inconsistent information on the clinical determinants of cognitive impairment (CI) in multiple sclerosis (MS). OBJECTIVE: The aim of this study was to compare the prevalence and profile of CI across MS disease subtypes and assess its clinical determinants. METHODS: Cognitive performance was assessed through the Brief Repeatable Battery and the Stroop test in consecutive patients with MS referred to six Italian centers...
October 13, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Deepak K Kaushik, Heather Y F Yong, Jennifer N Hahn, Claudia Silva, Steven Casha, R John Hurlbert, Francois H Jacques, Robert Lisak, Omar Khan, Carolina Ionete, Catherine Larochelle, Alex Prat, Amit Bar-Or, V Wee Yong
Extracellular matrix metalloproteinase inducer (EMMPRIN, CD147) is an inducer of matrix metalloproteinases and has roles in leukocyte activation and migration. We reported previously that in MS and its animal model, experimental autoimmune encephalomyelitis, cell surface-associated EMMPRIN was significantly elevated in leukocytes around inflammatory perivascular cuffs in the CNS. In this study we report that activated T-cells can secrete soluble form of EMMPRIN (sEMMPRIN) upon activation. As sEMMPRIN is also present in biological fluids, we determined whether sEMMPRIN is altered in the CSF and sera of MS subjects...
2016: PloS One
Caroline Massot, Hichem Khenioui, Olivier Agnani, Marc-Alexandre Guyot, Patrick Hautecoeur, Cécile Donze
PURPOSE: To report the prevalence and risk factors of stress urinary incontinence (SUI) and the prevalence of intrinsic sphincter deficiency in women with multiple sclerosis (MS). METHODS: We conducted a retrospective study. Female patients with MS, followed for lower urinary tract symptoms (LUTS) during a 15-year period were included. Demographic data, MS history, expanded disability status scale (EDSS) score at the urodynamic visit, obstetrical past, birth weight, LUTS, and urodynamic findings were collected...
September 2016: International Neurourology Journal
Johanna von Gumberz, Mina Mahmoudi, Kim Young, Sven Schippling, Roland Martin, Christoph Heesen, Susanne Siemonsen, Jan-Patrick Stellmann
BACKGROUND: Magnetic resonance imaging (MRI) is the best biomarker of inflammatory disease activity in relapsing remitting Multiple Sclerosis (RRMS) so far but the association with disability is weak. Appearance of new MRI-lesions is used to evaluate response to immunotherapies in individual patients as well as being the most common primary outcome in phase-2 trials. Measurements of brain atrophy show promising outcomes in natural cohort studies and some phase-2 trials. From a theoretical perspective they might represent irreversible neurodegeneration and be more closely associated with disability...
2016: PeerJ
Maxime Valet, Gaëtan Stoquart, Yumiko Glibert, Jean-Claude Hakizimana, Thierry Lejeune
OBJECTIVE: Fatigue is the most common and disabling symptom among patients suffering from multiple sclerosis (MS). From the initial stages of the disease, a physical deconditioning is also observed among these patients. The aim of this study is to assess the cardiorespiratory endurance (i.e. exercise tolerance functions) and self-reported fatigue, as well as their associations, among patients suffering from MS with mild disability (expanded disability status scale≤4). MATERIALS/PATIENTS AND METHODS: 21 patients with MS (15 women; age: 26-64 years, median 46 years; duration of disease: 0...
September 2016: Annals of Physical and Rehabilitation Medicine
Joel Kaye, Victor Piryatinsky, Tal Birnberg, Tal Hingaly, Emanuel Raymond, Rina Kashi, Einat Amit-Romach, Ignacio S Caballero, Fadi Towfic, Mark A Ator, Efrat Rubinstein, Daphna Laifenfeld, Aric Orbach, Doron Shinar, Yael Marantz, Iris Grossman, Volker Knappertz, Michael R Hayden, Ralph Laufer
Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington's disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell populations, especially astrocytes and microglia. Analysis of genome-wide expression data revealed activation of the aryl hydrocarbon receptor (AhR) pathway in laquinimod-treated mice. The AhR pathway modulates the differentiation and function of several cell populations, many of which play an important role in neuroinflammation...
October 11, 2016: Proceedings of the National Academy of Sciences of the United States of America
Valery Risson, Bhaskar Ghodge, Ian C Bonzani, Jonathan R Korn, Jennie Medin, Tanmay Saraykar, Souvik Sengupta, Deepanshu Saini, Melvin Olson
BACKGROUND: An enormous amount of information relevant to public health is being generated directly by online communities. OBJECTIVE: To explore the feasibility of creating a dataset that links patient-reported outcomes data, from a Web-based survey of US patients with multiple sclerosis (MS) recruited on open Internet platforms, to health care utilization information from health care claims databases. The dataset was generated by linkage analysis to a broader MS population in the United States using both pharmacy and medical claims data sources...
2016: Journal of Medical Internet Research
Antonio Candeliere-Merlicco, Francisco Valero-Delgado, Salvadora Martínez-Vidal, María Del Carmen Lastres-Arias, Eladio Aparicio-Castro, Francisco Toledo-Romero, Ramón Villaverde-González
BACKGROUND: The prevalence of multiple sclerosis (MS) varies throughout the world, and available epidemiological data suggest a progressively increasing prevalence of MS in Spain. The objective of this study was to calculate MS prevalence in Health District III of the autonomous community of Murcia in Spain. METHODS: This is an observational, cross-sectional, descriptive study. The prevalence of MS in Health District III in the Region of Murcia, which includes the municipalities of Lorca, Totana, Águilas, Puerto Lumbreras and Aledo, was calculated from the total population (171,040 inhabitants), and among native Spanish citizens only (137,659 persons)...
September 2016: Multiple Sclerosis and related Disorders
Mohammed S Razzaque
Vitamin D is a fat-soluble vitamin whose levels within the body are elevated following sunlight exposure. Numerous studies have shown that sunlight exposure can provide protection to a wide variety of diseases, ranging from different types of tumors to hypertension to type 1 diabetes to multiple sclerosis. Moreover, studies have shown that avoiding sunlight may influence the initiation and progression of these diseases. Avoidance of sunlight, coupled with the inclination towards consuming supplements, is becoming the primary choice to obtain vitamin D...
September 16, 2016: Journal of Steroid Biochemistry and Molecular Biology
C Solaro, E Trabucco, A Signori, V Martinelli, M Radaelli, D Centonze, S Rossi, M G Grasso, A Clemenzi, S Bonavita, A D'Ambrosio, F Patti, E D'Amico, G Cruccu, A Truini
BACKGROUND: Depression occurs in about 50% of patients with multiple sclerosis. The aims of this study was to investigate the prevalence of depressive symptoms in a multicenter MS population using the Beck Depression Inventory II (BDI II) and to identify possible correlations between the BDI II score and demographic and clinical variables. METHODS: Data were collected in a multi-center, cross-sectional study over a period of six months in six MS centers in Italy using BDI II...
2016: PloS One
So Jin Bing, Danbee Ha, Insun Hwang, Eunjin Park, Ginnae Ahn, Jie-Young Song, Youngheun Jee
Bearing pathologic and clinical similarities to human multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) is used as a murine model to test potential therapeutic agents for MS. Recently, we reported the protective effects of an acidic polysaccharide of Panax ginseng (APG) in C57BL/6 strain-dependent EAE, a model of primary progressive MS. In this study, we extend our previous findings on the therapeutic capacity of APG in relapsing-remitting EAE (rr-EAE), the animal model to closely mimic recurrent inflammatory demyelination lesions of relapsing-remitting MS...
2016: American Journal of Chinese Medicine
Nicolae Sarbu, Robert Y Shih, Robert V Jones, Iren Horkayne-Szakaly, Laura Oleaga, James G Smirniotopoulos
White matter diseases include a wide spectrum of disorders that have in common impairment of normal myelination, either by secondary destruction of previously myelinated structures (demyelinating processes) or by primary abnormalities of myelin formation (dysmyelinating processes). The pathogenesis of many white matter diseases remains poorly understood. Demyelinating disorders are the object of this review and will be further divided into autoimmune, infectious, vascular, and toxic-metabolic processes. Autoimmune processes include multiple sclerosis and related diseases: tumefactive demyelinating lesions, Balo concentric sclerosis, Marburg and Schilder variants, neuromyelitis optica (Devic disease), acute disseminated encephalomyelitis, and acute hemorrhagic leukoencephalopathy (Hurst disease)...
September 2016: Radiographics: a Review Publication of the Radiological Society of North America, Inc
Robert Hoepner, Eva M Kolb, Stefanie Dahlhaus, Kerstin Hellwig, Ortwin Adams, Ingo Kleiter, Anke Salmen, Ruth Schneider, Carsten Lukas, Andrew Chan, Joseph R Berger, Ralf Gold
OBJECTIVE: Progressive multifocal leukoencephalopathy (PML) is an emerging complication of immunosuppressive therapies, especially natalizumab in multiple sclerosis (MS). Factors associated with functional outcome of natalizumab-associated PML (natalizumab-PML) have not been sufficiently described. METHODS: We retrospectively analyzed medical records of all patients with natalizumab-PML (n = 32) treated in our hospital since 2009. Disability measured by Expanded Disability Status Scale (EDSS) at two different time points (highest available EDSS during PML and last available EDSS after PML diagnosis) served as functional outcome parameters...
September 6, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Ayman Tourbah, Christine Lebrun-Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Sèze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David-Axel Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frédéric Sedel, Jean Pelletier
BACKGROUND: Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. OBJECTIVE: To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. METHODS: Patients (n = 154) with a baseline Expanded Disability Status Scale (EDSS) score of 4.5-7 and evidence of disease worsening within the previous 2 years were randomised to 12-month MD1003 (100 mg biotin) or placebo thrice daily, followed by 12-month MD1003 for all patients...
September 1, 2016: Multiple Sclerosis: Clinical and Laboratory Research
Janos Groh, Hana C Friedman, Nadiya Orel, Chi Wang Ip, Stefan Fischer, Irene Spahn, Erik Schäffner, Michaela Hörner, David Stadler, Mathias Buttmann, Csanad Varallyay, László Solymosi, Michael Sendtner, Alan C Peterson, Rudolf Martini
Progressive forms of multiple sclerosis lead to chronic disability, substantial decline in quality of life and reduced longevity. It is often suggested that they occur independently of inflammation. Here we investigated disease progression in mouse models carrying PLP1 point mutations previously found in patients displaying clinical features of multiple sclerosis. These mouse models show loss-of-function of PLP1 associated with neuroinflammation; the latter leading to clinically relevant axonal degeneration, neuronal loss and brain atrophy as demonstrated by inactivation of the recombination activating gene 1...
August 29, 2016: Human Molecular Genetics
Peter Kosa, Danish Ghazali, Makoto Tanigawa, Chris Barbour, Irene Cortese, William Kelley, Blake Snyder, Joan Ohayon, Kaylan Fenton, Tanya Lehky, Tianxia Wu, Mark Greenwood, Govind Nair, Bibiana Bielekova
Therapeutic advance in progressive multiple sclerosis (MS) has been very slow. Based on the transformative role magnetic resonance imaging (MRI) contrast-enhancing lesions had on drug development for relapsing-remitting MS, we consider the lack of sensitive outcomes to be the greatest barrier for developing new treatments for progressive MS. The purpose of this study was to compare 58 prospectively acquired candidate outcomes in the real-world situation of progressive MS trials to select and validate the best-performing outcome...
2016: Frontiers in Neurology
Éva Sághy, Éva Sipos, Péter Ács, Kata Bölcskei, Krisztina Pohóczky, Ágnes Kemény, Zoltán Sándor, Éva Szőke, György Sétáló, Sámuel Komoly, Erika Pintér
Multiple sclerosis is a chronic inflammatory, demyelinating degenerative disease of the central nervous system. Current treatments target pathological immune responses to counteract the inflammatory processes. However, these drugs do not restrain the long-term progression of clinical disability. For this reason, new therapeutic approaches and identification of novel target molecules are needed to prevent demyelination or promote repair mechanisms. Transient Receptor Potential Ankyrin 1 (TRPA1) is a nonselective cation channel with relatively high Ca(2+) permeability...
August 29, 2016: Glia
Brenda Bertado-Cortés, Lyda Villamil-Osorio, Raúl Carrera-Pineda, Carlos Martínez-Cortés, José Guerrero-Cantera
BACKGROUND: Multiple sclerosis (MS) is a disease whose physiopathogenesis shows a complex interaction of genetic and environmental factors. Given that those factors have not been documented in our country, we describe the clinical and demographic characteristics from a sample of patients with MS. METHODS: We carried out an observational, descriptive, cross-sectional, and retrolective study in a Center for Demyelinating Diseases. We took the information from the clinical records of a sample of patients with multiple sclerosis, who arrived to the center from April 2014 to July 2015...
2016: Revista Médica del Instituto Mexicano del Seguro Social
George A Jelinek, Alysha M De Livera, Claudia H Marck, Chelsea R Brown, Sandra L Neate, Keryn L Taylor, Tracey J Weiland
OBJECTIVE: Emerging evidence links modifiable lifestyle risk factors to disease progression in multiple sclerosis (MS). We sought further evidence around this hypothesis through detailed analysis of the association with disability of lifestyle behaviours of a large international sample of people with MS. MATERIALS AND METHODS: A total of 2469 people with MS from 57 countries provided self-reported data via cross-sectional online survey on lifestyle (mostly with validated tools) and the primary outcome measure, disability (Patient Determined Disease Steps), categorised from 8 steps into 3 categories, mild, moderate and major disability...
2016: PloS One
Seyed Mahdi Mohammadi, Zeinab Shirvani Farsani, Rozita Dosti, Mohammad Ali Sahraian, Mehrdad Behmanesh
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system characterized by brain inflammation, demyelination and axonal loss. Neuropeptide Y (NPY) has a critical role in the maintenance of homeostasis in the immune system and coping of stress condition. In the current study we analyzed 188 patients suffering from MS and 204 unrelated healthy controls for two functional single nucleotide polymorphisms (SNPs), NPY 20T>C (rs16139) and NPY -485T>C (rs16147) using PCR-RFLP and Mismatch PCR-RFLP methods...
August 8, 2016: Neuropeptides
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"